Gulf International Bank (Uk) LTD Bei Gene, Ltd. Transaction History

Gulf International Bank (Uk) LTD

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 24, 2022	BUY	$248.56 - $389.34 $298,272 - $467,207	1,200 Added 20.0%	7,200 $1.95 Million
Q4 2020 Feb 12, 2021	SELL	$221.31 - $316.61 $863,109 - $1.23 Million	-3,900 Reduced 39.39%	6,000 $1.55 Million
Q3 2020 Oct 21, 2020	BUY	$189.18 - $286.44 $189,180 - $286,440	1,000 Added 11.24%	9,900 $2.84 Million
Q4 2018 Jan 08, 2019	BUY	$107.01 - $175.15 $952,389 - $1.56 Million	8,900 New	8,900 $1.25 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.9B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Gulf International Bank (Uk) LTD, based on Form 13F filings with the SEC.

Stay updated on Gulf International Bank (Uk) LTD with notifications on news.